Your browser doesn't support javascript.
loading
Clinical next generation sequencing to identify actionable aberrations in a phase I program.
Boland, Genevieve M; Piha-Paul, Sarina A; Subbiah, Vivek; Routbort, Mark; Herbrich, Shelley M; Baggerly, Keith; Patel, Keyur P; Brusco, Lauren; Horombe, Chacha; Naing, Aung; Fu, Siqing; Hong, David S; Janku, Filip; Johnson, Amber; Broaddus, Russell; Luthra, Raja; Shaw, Kenna; Mendelsohn, John; Mills, Gordon B; Meric-Bernstam, Funda.
Afiliación
  • Boland GM; Division of Surgical Oncology, Department of Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
  • Piha-Paul SA; Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Subbiah V; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Routbort M; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Herbrich SM; Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Baggerly K; Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Patel KP; Department of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Brusco L; Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Horombe C; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Naing A; Department of Sheikh Khalifa Bin Zayed Al Nahyan Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Fu S; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Hong DS; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Janku F; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Johnson A; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Broaddus R; Department of Sheikh Khalifa Bin Zayed Al Nahyan Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Luthra R; Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Shaw K; Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Mendelsohn J; Department of Sheikh Khalifa Bin Zayed Al Nahyan Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Mills GB; Department of Sheikh Khalifa Bin Zayed Al Nahyan Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Meric-Bernstam F; Department of Sheikh Khalifa Bin Zayed Al Nahyan Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Oncotarget ; 6(24): 20099-110, 2015 Aug 21.
Article en En | MEDLINE | ID: mdl-26015395
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Secuenciación de Nucleótidos de Alto Rendimiento / Mutación / Neoplasias Tipo de estudio: Guideline Límite: Humans Idioma: En Revista: Oncotarget Año: 2015 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Secuenciación de Nucleótidos de Alto Rendimiento / Mutación / Neoplasias Tipo de estudio: Guideline Límite: Humans Idioma: En Revista: Oncotarget Año: 2015 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Estados Unidos